Literature DB >> 17005701

Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.

Philip L Leopold1, Rebecca L Wendland, Theresa Vincent, Ronald G Crystal.   

Abstract

Neutralization of adenovirus (Ad) by anti-Ad neutralizing antibodies in serum involves formation of Ad-immune complexes that prevent the virus from interacting with target cells. We hypothesized that Ad-immune complexes likely contain viable Ad vectors which, although no longer capable of gaining access to receptors on target cells, may be able to express transgenes in cells bearing Fc receptors for immunoglobulins, i.e., that antibody-based "neutralization" of Ad vectors may be circumvented by the Fc receptor pathway. To test this hypothesis, we expressed the Fcgamma receptor IIA (FcgammaR) in A549 lung epithelial cells or human dermal fibroblasts and evaluated gene transfer in the presence of human neutralizing anti-Ad serum. FcgammaR-expressing cells bound and internalized copious amounts of Ad, with a distinct population of internalized Ad trafficking to the nucleus. The dose-response curves for inhibition of gene transfer revealed that FcgammaR-expressing cells required a more-than-10-fold higher concentration of anti-Ad serum to achieve 50% inhibition of Ad-encoded beta-galactosidase expression compared with non-FcgammaR-expressing cells. The discrepancy between neutralization of Ad during infection of FcgammaR-expressing cells and neutralization of Ad during infection of non-FcgammaR-expressing cells occurred with either heat-inactivated or non-heat-inactivated sera, was blocked by addition of purified Fc domain protein, and did not require the cytoplasmic domain of FcgammaR, suggesting that immune complex internalization proceeded via endocytosis rather than phagocytosis. FcgammaR-mediated infection by Ad-immune complexes did not require expression of the coxsackie virus-Ad receptor (CAR) since similar data were obtained when CAR-deficient human dermal fibroblasts were engineered to express FcgammaR. However, interaction of the Ad penton base with cell surface integrins contributed to the difference in neutralization between FcgammaR-expressing and non-FcgammaR-expressing cells. The data indicate that complexes formed from Ad and anti-Ad neutralizing antibodies, while compromised with respect to infection of non-FcgammaR-expressing target cells, maintain the potential to transfer genes to FcgammaR-expressing cells, with consequent expression of the transgene. The formation of Ad-immune complexes that can target viable virus to antigen-presenting cells may account for the success of Ad-based vaccines administered in the presence of low levels of neutralizing anti-Ad antibody.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005701      PMCID: PMC1617312          DOI: 10.1128/JVI.00512-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

Review 1.  Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.

Authors:  Ayato Takada; Yoshihiro Kawaoka
Journal:  Rev Med Virol       Date:  2003 Nov-Dec       Impact factor: 6.989

2.  Postinternalization inhibition of adenovirus gene expression and infectious virus production in human T-cell lines.

Authors:  Adrienne L McNees; Jeff A Mahr; David Ornelles; Linda R Gooding
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines.

Authors:  Miguel Aste-Amézaga; Andrew J Bett; Fubao Wang; Danilo R Casimiro; Joseph M Antonello; Deepa K Patel; Elayne C Dell; Laura L Franlin; Nancy M Dougherty; Philip S Bennett; Helen C Perry; Mary-Ellen Davies; John W Shiver; Paul M Keller; Mark D Yeager
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

5.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

6.  FcgammaRII expression on follicular dendritic cells and immunoreceptor tyrosine-based inhibition motif signaling in B cells.

Authors:  Yüksel Aydar; Jiuhua Wu; Jingmei Song; Andras K Szakal; John G Tew
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

7.  Specific antibodies modulate the interactions of adenovirus type 5 with dendritic cells.

Authors:  S Mercier; H Rouard; M H Delfau-Larue; M Eloit
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

8.  Human rhinovirus type 2-antibody complexes enter and infect cells via Fc-gamma receptor IIB1.

Authors:  Günther Baravalle; Marianne Brabec; Luc Snyers; Dieter Blaas; Renate Fuchs
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.

Authors:  Stefan Worgall; Annette Busch; Michael Rivara; David Bonnyay; Philip L Leopold; Robert Merritt; Neil R Hackett; Peter W Rovelink; Joseph T Bruder; Thomas J Wickham; Imi Kovesdi; Ronald G Crystal
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more
  10 in total

1.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Authors:  William C Adams; Emily Bond; Menzo J E Havenga; Lennart Holterman; Jaap Goudsmit; Gunilla B Karlsson Hedestam; Richard A Koup; Karin Loré
Journal:  J Gen Virol       Date:  2009-03-12       Impact factor: 3.891

3.  The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy.

Authors:  Richard G Vile
Journal:  Mol Ther       Date:  2018-03-21       Impact factor: 11.454

4.  Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Authors:  Fang Fang; Ping Chen; Xin Wu; Li Yang; Xun Yang; Zhen-Xiang Xi; Bin-Wen Zhou; Xi-Kun Zhou; Zhi-Yong Qian; Bo Xiao; Yu-Quan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

5.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

6.  Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

Authors:  Ramil Sapinoro; Ketna Volcy; W W Shanaka I Rodrigo; Jacob J Schlesinger; Stephen Dewhurst
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

7.  Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A.

Authors:  Xiangyun He; Xingmin Sun; Jufang Wang; Xiaoning Wang; Quanshun Zhang; Saul Tzipori; Hanping Feng
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

8.  Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.

Authors:  Caijun Sun; Liqiang Feng; Yinfeng Zhang; Lijun Xiao; Weiqi Pan; Chufang Li; Linqi Zhang; Ling Chen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

9.  Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.

Authors:  Anil Babu Korrapati; Gokul Swaminathan; Aarti Singh; Navin Khanna; Sathyamangalam Swaminathan
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

10.  Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.

Authors:  Matthieu Perreau; Giuseppe Pantaleo; Eric J Kremer
Journal:  J Exp Med       Date:  2008-11-03       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.